Show simple item record

dc.contributor.authorRECOVERY Collaborative Group
dc.date.accessioned2021-06-04T13:11:00Z
dc.date.available2021-06-04T13:11:00Z
dc.date.issued2021-05-07
dc.identifier.citationRECOVERY Collaborative Group 2021 , ' Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ' , The Lancet , vol. 397 , no. 10285 , pp. 1637-1645 . https://doi.org/10.1016/S0140-6736(21)00676-0en
dc.identifier.issn0140-6736
dc.identifier.otherPURE: 194432920
dc.identifier.otherPURE UUID: 63c9c8a2-7f0d-44ca-bad7-85b4bd0a1a57
dc.identifier.otherBibtex: 20211637
dc.identifier.otherPubMed: 33933206
dc.identifier.otherPubMedCentral: PMC8084355
dc.identifier.otherORCID: /0000-0002-1397-4272/work/95222694
dc.identifier.otherScopus: 85104923041
dc.identifier.urihttps://hdl.handle.net/2164/16630
dc.descriptionAcknowledgments Above all, we thank the thousands of patients who participated in this study. We also thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at 176 NHS hospital organisations across the whole of the UK, supported by staff at the National Institute of Health Research (NIHR) Clinical Research Network, NHS DigiTrials, Public Health England, Department of Health & Social Care, the Intensive Care National Audit & Research Centre, Public Health Scotland, National Records Service of Scotland, the Secure Anonymised Information Linkage at the University of Swansea, and the NHS in England, Scotland, Wales, and Northern Ireland. The RECOVERY trial is supported by a grant to the University of Oxford from UK Research and Innovation–NIHR (Grant reference: MC_PC_19056) and by core funding provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill & Melinda Gates Foundation, the Department for International Development, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. TJ is supported by a grant from UK Medical Research Council (MC_UU_0002/14) and an NIHR Senior Research Fellowship (NIHR-SRF-2015-08-001). WSL is supported by core funding provided by NIHR Nottingham Biomedical Research Centre. AbbVie contributed some supplies of lopinavir–ritonavir for use in this study. Roche Products supported the trial through the provision of tocilizumab. REGEN-COV2 was provided for this study by Regeneron. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care, or Roche Products. Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research. The writing committee and trial steering committee are listed at the end of this manuscript and a complete list of collaborators in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is provided in the appendix (pp 2–25)en
dc.format.extent9
dc.language.isoeng
dc.relation.ispartofThe Lanceten
dc.rightsCopyright © 2021 Published by Elsevier Ltd. All rights reserved. This is an Open Access article under the CC BY 4.0 license.https://creativecommons.org/licenses/by/4.0/en
dc.subjectR Medicineen
dc.subjectMedical Research Council (MRC)en
dc.subjectNational Institute for Health Research (NIHR)en
dc.subject.lccRen
dc.titleTocilizumab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trialen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Health Services Research Uniten
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1016/S0140-6736(21)00676-0


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record